Heading To A Device AdComm? US FDA Details Key Deadlines In Final Guidance
Executive Summary
The newly finalized guidance document discusses how manufacturers should prepare for a panel meeting and the finer points on how the meetings are conducted. It also incorporates some updates from the 21st Century Cures Act.
You may also be interested in...
CDRH Lays Out Inner Workings Of Device Advisory Panels
In a draft guidance, CDRH explains how it consults with its device advisory panels, types of panel meetings and deadlines for participating firms. The guidance comes following recent CDRH-industry discussions on the impact of the panel process on PMA decision times.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.